ESC Congress 2018

25 - 29 August 2018, Munich - Germany

Session Details

Controversies in cardiovascular risk assessment and prevention
Tue 28 Aug 10:05 - 10:55 Risk Factors and Prevention – Cardiovascular Risk Assessment Moderated Posters, Abstract-based Programme Moderated Poster Station - Poster Area
Chairpersons: Angela MAAS (Nijmegen, Netherlands), Axel SCHMERMUND (Frankfurt Am Main, Germany)
Learning Objectives: Moderated Posters are on display from 08:30 to 12:30 on the plasma screen of the topic related Moderated Poster station. During the moderated poster session (10:05-10:55), from a large plasma screen, Presenters will summarise their research within 3 minutes and then address questions from the Chairpersons and Audience.

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Related documents
10:05P5082Increased mortality despite successful multifactorial cardiovascular risk reduction in healthy men. 40-year follow-up of the Helsinki businessmen study intervention trialTimo STRANDBERG (Oulu, Finland)
10:05P5083Assessing cardiovascular risk in people with atherosclerotic vascular disease on intensive statin therapyBorislava MIHAYLOVA (Oxford, United Kingdom)
10:05P5084Added predictive value of follow-up blood-pressure measurements after alteration of therapy on cardiovascular risk in patients with hypertensionNicole Elise Maria JASPERS (Utrecht, Netherlands)
10:05P5085Optimizing outreach strategy to identify individuals at risk for diabetes and/or cardiovascular disease: a study of the Sodertalje municipality in SwedenBahira SHAHIM (Stockholm, Sweden)
10:05P5086Associations between very low concentrations of LDL-Cholesterol, hsCRP and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) studyMaciej BANACH (Lodz, Poland)
10:05P5087Sex hormone-binding globulin, aging, and cardiovascular riskElif ARIBAS (Oisterwijk, Netherlands)
10:05P5088Significant reduction of Framingham risk score in hypogonadal men receiving long-term testosterone therapy: real-life evidence from a 10-year registryFarid SAAD (Berlin, Germany)